Amivantamab Tied to Diverse Dermatologic Events in NSCLC

Published Date: 20 Feb 2026

Treatment with amivantamab is associated with a broad spectrum of dermatologic adverse events that can be severe in patients with non-small cell lung cancer, a real-world study shows.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

2.

Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.

3.

For treatment, the majority of cancer patients choose complementary therapies.

4.

Study reveals that older women frequently receive an incorrect breast cancer diagnosis.

5.

AI Model as Effective as Radiologists in Detecting Prostate Cancer on MRI


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot